Want to see PBH full AI Analyst Report?
Top Page
Prestige Consumer Healthcare
(NYSE:PBH)
Select Model
Select Model
Rating:77Outperform
Price Target:
$60.00
▲(19.05% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by strong financial performance (profitability and robust free cash flow) and a supportive earnings outlook with raised acquisition-driven guidance. Technicals are constructive but show signs of being stretched short term (high Stochastic). Valuation appears reasonable on P/E, though no dividend yield data is provided.
Positive Factors
Acquisition-led portfolio expansion
The acquisitions expand PBH into nasal strips and therapeutic skincare while adding established brands and geographic reach. Their expected accretion and targeted low- to mid-30s% EBITDA margins could strengthen the portfolio over multiple years.
Negative Factors
Meaningful leverage and financing burden
Acquisition financing materially increases obligations, while management expects roughly $100M of additional interest expense and leverage near 4x. This can constrain investment flexibility and make earnings more sensitive to integration results and cash-flow performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Acquisition-led portfolio expansion
The acquisitions expand PBH into nasal strips and therapeutic skincare while adding established brands and geographic reach. Their expected accretion and targeted low- to mid-30s% EBITDA margins could strengthen the portfolio over multiple years.
Read all positive factors
Prestige Consumer Healthcare (PBH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.40B
Dividend YieldN/A
Average Volume (3M)783.95K
Price to Earnings (P/E)14.4
Beta (1Y)0.35
Revenue Growth-1.36%
EPS Growth-16.45%
CountryUS
Employees890
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)3.59
Shares Outstanding47,374,523
10 Day Avg. Volume630,153
30 Day Avg. Volume783,950
Financial Highlights & Ratios
PEG Ratio-1.67
Price to Book (P/B)1.52
Price to Sales (P/S)2.64
P/FCF Ratio11.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$72.00Price Target Upside42.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.58
Revenue Forecast (FY)$1.30B
Prestige Consumer Healthcare Business Overview & Revenue Model
Company Description
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The compan...
How the Company Makes Money
PBH makes money primarily by selling branded consumer healthcare products (mainly OTC medications and related health items) to retailers, wholesalers, and distributors. Revenue is generated when PBH ships finished goods under its brands into retai...
Prestige Consumer Healthcare Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call communicated a broadly positive operational and financial start to fiscal '27: reported revenue and adjusted EBITDA grew, record adjusted free cash flow was delivered, and two strategic acquisitions (Breathe Right and LaCorium) were closed and are expected to meaningfully expand revenue and margins. Management acknowledged notable near-term challenges — most prominently Clear Eyes supply variability from Pillar5 integration, YoY gross margin pressure from transportation costs, international distributor timing, and elevated debt/interest costs — but provided specific remediation and integration plans, maintained organic growth guidance (1%–3%) and raised reported guidance driven by acquisitions. Given the strong cash flow, completed integration of Breathe Right, accretive acquisition profile, and maintained outlook despite manageable headwinds, the overall tone and expected trajectory are positive.Positive Updates
Reported Revenue Growth
Q1 revenue of $265.7M, up 6.5% versus $249.5M a year ago; organic revenue growth of 3.2% excluding FX and the Breathe Right acquisition.
Negative Updates
Clear Eyes Supply Disruption
Clear Eyes supply remained volatile and constrained in Q1 due to Pillar5 integration/investments; Clear Eyes now represents less than 3% of sales and recovery is expected to be multi-quarter/multi-year with output variability in H1 and stabilization targeted in H2.
Read all updates
Q1-2027 Updates
Positive
Negative
Reported Revenue Growth
Q1 revenue of $265.7M, up 6.5% versus $249.5M a year ago; organic revenue growth of 3.2% excluding FX and the Breathe Right acquisition.
Read all positive updates
Company Guidance
Prestige updated fiscal 2027 guidance calling for revenues of $1.29–$1.315 billion (organic growth 1–3%), driven by the Breathe Right and LaCorium acquisitions which are expected to contribute roughly $190 million this year (Breathe Right ~ $200M annualized; LaCorium ~ $40M) and add more than 20% to annualized revenue; Q2 revenue is guided to $328–$331 million. Full‑year adjusted diluted EPS is $4.55–$4.65 (Q2 EPS ~$1.06–$1.08); adjusted gross margin is expected to be just over 57% for Q2 and the full year (Q1 was ~55%, down 120 bps YoY); A&M spend is guided to ~14.5% of sales for Q2/FY (Q1 A&M was $34.7M or 13%); adjusted G&A ~10% of sales for the year (Q1: 11.5%). The company expects at least $270 million of adjusted free cash flow in fiscal ’27 (Q1 record FCF $83.7M), a year‑end leverage ratio just below 4x (net debt ~$2.0B at June 30), and flagged higher interest and amortization in the back half of the year of roughly $100M and $33M respectively, while noting steps to extend maturities (earliest now 2031), issue $400M of new notes and prioritize debt paydown.Prestige Consumer Healthcare Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.10B | 1.09B | 1.14B | 1.13B | 1.13B | 1.09B |
| Gross Profit | 588.49M | 574.64M | 634.46M | 624.45M | 625.29M | 620.65M |
| EBITDA | 312.70M | 331.11M | 361.99M | 373.86M | 7.87M | 358.84M |
| Net Income | 172.01M | 190.30M | 214.60M | 209.34M | -82.31M | 205.38M |
Balance Sheet | ||||||
| Total Assets | 4.57B | 3.55B | 3.40B | 3.32B | 3.35B | 3.67B |
| Cash, Cash Equivalents and Short-Term Investments | 89.13M | 63.87M | 97.88M | 46.47M | 58.49M | 27.18M |
| Total Debt | 2.06B | 1.05B | 1.04B | 1.14B | 1.37B | 1.51B |
| Total Liabilities | 2.65B | 1.66B | 1.57B | 1.66B | 1.91B | 2.09B |
| Stockholders Equity | 1.92B | 1.89B | 1.83B | 1.66B | 1.45B | 1.58B |
Cash Flow | ||||||
| Free Cash Flow | 235.36M | 246.45M | 243.29M | 239.38M | 221.93M | 250.28M |
| Operating Cash Flow | 249.40M | 257.63M | 251.51M | 248.93M | 229.72M | 259.92M |
| Investing Cash Flow | -1.20B | -136.84M | -17.45M | -20.11M | -11.58M | -256.51M |
| Financing Cash Flow | 898.67M | -156.06M | -182.07M | -241.01M | -185.85M | -7.57M |
Prestige Consumer Healthcare Technical Analysis
Positive
50.40
Price Trends
49.60
Positive
51.32
Positive
57.30
Negative
Market Momentum
0.48
Positive
52.45
Neutral
17.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Positive. The current price of 50.4 is below the 20-day moving average (MA) of 51.66, above the 50-day MA of 49.60, and below the 200-day MA of 57.30, indicating a neutral trend. The MACD of 0.48 indicates Positive momentum. The RSI at 52.45 is Neutral, neither overbought nor oversold. The STOCH value of 17.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBH.
Prestige Consumer Healthcare Risk Analysis
Prestige Consumer Healthcare disclosed 25 risk factors in its most recent earnings report. Prestige Consumer Healthcare reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prestige Consumer Healthcare Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $2.40B | 14.40 | 9.22% | ― | -1.36% | -16.45% | |
76 Outperform | $101.35B | 22.75 | -194.39% | 0.39% | 8.84% | 48.98% | |
69 Neutral | $9.94B | 25.81 | 12.37% | ― | 6.49% | 10.41% | |
69 Neutral | $2.42B | 36.16 | 30.80% | ― | 10.31% | ― | |
65 Neutral | $54.65B | 32.30 | -59.73% | 0.90% | 14.23% | 12.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
PBH
Prestige Consumer Healthcare
51.68
-13.77
-21.04%
CAH
Cardinal Health
234.85
84.84
56.56%
HSIC
Henry Schein
89.29
21.08
30.90%
MCK
McKesson
853.71
150.57
21.41%
GRDN
Guardian Pharmacy Services, Inc. Class A
37.97
11.68
44.43%
Prestige Consumer Healthcare Corporate Events
Business Operations and StrategyExecutive/Board Changes
Prestige Consumer Healthcare Announces Operations Leadership Transition
Neutral
Aug 14, 2026
On August 10, 2026, Prestige Consumer Healthcare Inc. announced that Jeffrey Zerillo had informed the company of his decision to retire from his role as Senior Vice President, Operations. His retirement from this position and all other roles at th...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
Prestige Consumer Healthcare Lifts Outlook on Acquisition-Driven Growth
Positive
Aug 6, 2026
Prestige Consumer Healthcare reported that first-quarter fiscal 2027 revenue for the period ended June 30, 2026 rose 6.5% year on year to $265.7 million, with organic sales up 3.2%, driven by broad-based strength in gastrointestinal, dermatologica...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Prestige Consumer Healthcare Completes LaCorium Acquisition, Refinances Debt
Positive
Jul 6, 2026
On July 1, 2026, Prestige Consumer Healthcare and its subsidiary Prestige Brands amended their term loan credit agreement to permit up to $95 million in additional term loans. These funds were designated to help finance the previously announced ac...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Prestige Consumer Healthcare Completes Breathe Right Brand Acquisition
Positive
Jun 16, 2026
Prestige Consumer Healthcare Inc. completed the acquisition of the Breathe Right brand and certain other brands from Foundation Consumer Healthcare on June 12, 2026, for $1.045 billion in cash, or about $900 million net of anticipated tax benefits...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.